Please login to the form below

Not currently logged in

idiopathic pulmonary fibrosis

This page shows the latest idiopathic pulmonary fibrosis news and features for those working in and with pharma, biotech and healthcare.

AZ makes gene therapy move with 4DMT alliance

AZ makes gene therapy move with 4DMT alliance

Last year, AZ also paid 25m upfront in a research deal with German biotech Ethris to develop mRNA drugs for respiratory diseases, including asthma, chronic obstructive pulmonary disease (COPD), and idiopathic ... pulmonary fibrosis (IPF).

Latest news

More from news
Approximately 5 fully matching, plus 43 partially matching documents found.

Latest Intelligence

  • Deal Watch June 2016 Deal Watch June 2016

    pulmonary fibrosis (IPF) with cough. ... licence, collaboration. 2, 560. Afferent Pharmaceuticals/ Merck &Co. AF-219, oral P2X3 antagonist for chronic cough (p2b) and idiopathic pulmonary fibrosis (p2) with cough, and other compounds.

  • Pharma deals in August 2015 Pharma deals in August 2015

    PRM 151 is under development for the treatment of idiopathic pulmonary fibrosis. ... Acquisition ‐ company. 1300. Promedior. BMS. PRM 151 recombinant pentraxin‐ 2 protein for idiopathic pulmonary fibrosis and myelofibrosis.

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    Omega Pharma / Perrigo. OTC portfolio. Company acquisition. 4, 500. Cystic Fibrosis Foundation /Royalty Pharma. ... Company acquisition. 840. Galecto Biotech / BMS. TD139 galectin-3 inhibitor for Idiopathic pulmonary fibrosis.

  • Deal Watch table for August 2014 Deal Watch table for August 2014

    InterMune/ Roche. Company acquisition. Pirfenidone for idiopathic pulmonary fibrosis (IPF) (approved EU, Canada).

  • Pharma deals during August 2014 Pharma deals during August 2014

    This brings a much needed boost to its respiratory portfolio, which currently consists of Pulmozyme (cystic fibrosis) and Xolair (severe asthma) and products in clinical development, eg lebrikizumab (severe asthma). ... Pirfenidone is under regulatory

More from intelligence
Approximately 0 fully matching, plus 7 partially matching documents found.

Latest from PMHub

  • Innovation and technology at Roche’s “Air Spain” Event

    The event Air Spain organised by Roche, spoke about how to optimise research, knowledge and treatment of idiopathic pulmonary fibrosis.

  • Understanding the "Big Picture"

    For example, a technology originally intended to monitor the presence of lung fibrosis in idiopathic pulmonary fibrosis (IPF) but then finding utility in other fibrotic lung diseases. ... Keeping with the example of fibrosis, if the targets are viable,

More from PMHub
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts


Add my company
Anatomy Health

We are a health information design consultancy focused on developing simple, accessible and inclusive patient communications. From evaluating existing patient...

Latest intelligence

Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...